|Bid||18.10 x 1800|
|Ask||18.26 x 1000|
|Day's Range||18.10 - 18.40|
|52 Week Range||12.43 - 20.93|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||22.37|
|Forward Dividend & Yield||0.84 (4.61%)|
|Ex-Dividend Date||Mar 30, 2020|
|1y Target Est||23.60|
Takeda will leverage its manufacturing capabilities in Japan to produce Novavax's coronavirus treatment candidate.
New York’s school districts will welcome students back into classrooms in the fall, Governor Andrew Cuomo announced on Friday, as the former coronavirus epicenter continues on its recovery.
The biotech company (NVAX)has announced agreements to join with other drugmakers to market its drugs in Japan, India, and low- and middle-income countries around the world. The news came days after Novavax (ticker: NVAX) released data on its Covid-19 vaccine that some analysts said had set it up as perhaps the most promising among the experimental vaccines for which preliminary human data is available. Novavax announced a deal on Thursday with the Serum Institute of India by which the companies expect to sell 1 billion doses of the Covid-19 vaccine to India and other low- and mid-income countries.